{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T15:49:41Z","timestamp":1764344981428,"version":"3.46.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,28]]},"DOI":"10.7759\/cureus.98018","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T15:46:10Z","timestamp":1764344770000},"source":"Crossref","is-referenced-by-count":0,"title":["Janus Kinase Inhibitor Discontinuation at a UK Tertiary Centre: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Katie","family":"Bland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameen","family":"Jubber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arumugam","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020, 79:685-99. 10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz DM","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017, 17:78. 10.1038\/nrd.2017.267","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor PC","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al.. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017, 376:652-62. 10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen JS","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al.. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019, 393:2303-11. 10.1016\/S0140-6736(19)30419-2","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe B","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, et al.. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021, 80:848-58. 10.1136\/annrheumdis-2020-219214","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224670","article-title":"Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)","volume":"83","author":"Aymon R","year":"2024","unstructured":"Aymon R, Mongin D, Bergstra SA, et al.. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study). Ann Rheum Dis. 2024, 83:421-8. 10.1136\/ard-2023-224670","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg SR","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al.. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022, 386:316-26. 10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023, 82:3-18. 10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"ref9","unstructured":"Janus kinase (JAK) inhibitors. new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality. (2023). Accessed: 2025: https:\/\/www.gov.uk\/drug-safety-update\/janus-kinase-jak-inhibitors-new-measures-to-reduce-risks-of-major-cardiovascula...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo ML","year":"1995","unstructured":"Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:44-8. 10.1002\/art.1780380107","journal-title":"Arthritis Rheum"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.11.1101","article-title":"Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score","volume":"35","author":"Prevoo ML","year":"1996","unstructured":"Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996, 35:1101-5. 10.1093\/rheumatology\/35.11.1101","journal-title":"Br J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.7.589","article-title":"Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis","volume":"32","author":"Prevoo ML","year":"1993","unstructured":"Prevoo ML, van Riel PL, van 't Hof MA, van Rijswijk MH, van Leeuwen MA, Kuper HH, van de Putte LB. Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol. 1993, 32:589-94. 10.1093\/rheumatology\/32.7.589","journal-title":"Br J Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.2.177","article-title":"Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis","volume":"51","author":"van der Heijde DM","year":"1992","unstructured":"van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis. 1992, 51:177-81. 10.1136\/ard.51.2.177","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"van der Heijde DM","year":"1990","unstructured":"van der Heijde DM, van 't Hof MA, van Riel PL, et al.. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990, 49:916-20. 10.1136\/ard.49.11.916","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123494","article-title":"The retention rate and safety of JAK inhibitors in rheumatoid arthritis: real world data from a monocentric cohort","volume":"13","author":"Donzella D","year":"2024","unstructured":"Donzella D, Bellis E, Crepaldi G, et al.. The retention rate and safety of JAK inhibitors in rheumatoid arthritis: real world data from a monocentric cohort. J Clin Med. 2024, 13:10.3390\/jcm13123494","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration","volume":"81","author":"Lauper K","year":"2022","unstructured":"Lauper K, Iudici M, Mongin D, et al.. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration. Ann Rheum Dis. 2022, 81:1358-66. 10.1136\/annrheumdis-2022-222586","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0306714","article-title":"Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis","volume":"19","author":"Saito K","year":"2024","unstructured":"Saito K, Yoshida S, Ebina H, et al.. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis. PLoS One. 2024, 19:e0306714. 10.1371\/journal.pone.0306714","journal-title":"PLoS One"},{"key":"ref18","unstructured":"Adverse event. (2025). Accessed. 2025: https:\/\/www.ema.europa.eu\/en\/glossary-terms\/adverse-event."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071923","article-title":"Race, ethnicity, and pharmacogenomic variation in the United States and the United Kingdom","volume":"15","author":"Sharma S","year":"2023","unstructured":"Sharma S, Mari\u00f1o-Ram\u00edrez L, Jordan IK. Race, ethnicity, and pharmacogenomic variation in the United States and the United Kingdom. Pharmaceutics. 2023, 15:1923. 10.3390\/pharmaceutics15071923","journal-title":"Pharmaceutics"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg354","article-title":"Ethnic differences in responses to disease modifying drugs","volume":"42","author":"Helliwell PS","year":"2003","unstructured":"Helliwell PS, Ibrahim G. Ethnic differences in responses to disease modifying drugs. Rheumatology (Oxford). 2003, 42:1197-201. 10.1093\/rheumatology\/keg354","journal-title":"Rheumatology (Oxford)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20024","article-title":"Are there any ethnic differences in the response to baricitinib for the treatment of rheumatoid arthritis?","volume":"13","author":"Zahir Hussain WH","year":"2021","unstructured":"Zahir Hussain WH, Jubber A, Moorthy A. Are there any ethnic differences in the response to baricitinib for the treatment of rheumatoid arthritis?. Cureus. 2021, 13:e20024. 10.7759\/cureus.20024","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/385206-janus-kinase-inhibitor-discontinuation-at-a-uk-tertiary-centre-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T15:46:11Z","timestamp":1764344771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/385206-janus-kinase-inhibitor-discontinuation-at-a-uk-tertiary-centre-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.98018","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}